TY  - JOUR
AU  - Robertson, John F. R.
AU  - Bondarenko, Igor M.
AU  - Trishkina, Ekaterina
AU  - Dvorkin, Mikhail
AU  - Panasci, Lawrence
AU  - Manikhas, Alexey
AU  - Shparyk, Yaroslav
AU  - Cardona-Huerta, Servando
AU  - Cheung, Kwok-Leung
AU  - Philco-Salas, Manuel Jesus
AU  - Ruiz-Borrego, Manuel
AU  - Shao, Zhimin
AU  - Noguchi, Shinzaburo
AU  - Rowbottom, Jacqui
AU  - Stuart, Mary
AU  - Grinsted, Lynda M.
AU  - Fazal, Mehdi
AU  - Ellis, Matthew J.
PY  - 2016
DO  - 10.1016/S0140-6736(16)32389-3
SN  - 0140-6736
UR  - http://hdl.handle.net/10668/18892
T2  - Lancet
AB  - Background Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free survival...
LA  - en
PB  - Elsevier science inc
KW  - First-line therapy
KW  - Postmenopausal women
KW  - Endocrine-therapy
KW  - 1st-line therapy
KW  - Tamoxifen
KW  - Letrozole
KW  - Superior
KW  - Survival
KW  - Efficacy
TI  - Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
TY  - research article
VL  - 388
ER  -